Plus, Simon Property Group is acquiring Taubman Centers for $3.6 billion, and Eli Lilly shares are down after a failed trial for its Alzheimer’s drug candidate.
Read MoreBuy Target – $24.00 or better Sell Target – TradersPro Sell Signal Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total […]
Read MorePlus, the coronavirus now has more than 20,000 confirmed cases globally, and Alphabet shares are lower after the Google parent reported lower-than-expected revenues.
Read MoreBuy Target – $15.50 or better Sell Target – TradersPro Sell Signal Molecular Templates, Inc., a clinical stage oncology company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is […]
Read MoreEach of these biotechs are developing a vaccine for the rapidly-spreading coronavirus, and analysts say all 3 have minimum double-digit upside ahead.
Read MorePlus, there are now 8,200 confirmed cases of the Chinese coronavirus, Facebook reported a 51% rise in expenses, and GM said it’s bringing back the Hummer.
Read MorePlus, the coronavirus now has more than 6,000 confirmed cases, Apple delivered a blowout quarter, and Boeing said costs related to the grounding of its 737 Max plane have exceeded $18 billion.
Read MoreBuy Target – $4.25 or better Sell Target – TradersPro Sell Signal Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases in the United States. Its lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the […]
Read MorePlus, the Chinese coronavirus has spread to more than 4,600 patients, U.S. consumer confidence grew this month, and the U.K. is allowing vendors to use Huawei hardware in the build-out of the country’s 5G network.
Read MorePlus, Trump’s impeachment trial gets underway in the Senate today, the World Economic Forum in Davos kicked off, and earnings season marches on with Halliburton reporting.
Read MorePlus, Trump’s Senate impeachment trial formally gets underway today, White House trade advisor Peter Navarro spelled out what the U.S. is looking for in the next round of trade negotiations with China, and Morgan Stanley reported an earnings beat.
Read MorePlus, mortgage applications surged in the first week of the year, Goldman Sachs delivered an earnings beat, and Target’s holiday sales disappointed.
Read MorePlus, China and the U.S. are set to sign the “phase one” trade agreement this week, Iran admitted it mistakenly shot down the Ukraine-bound passenger jet, and two aerospace suppliers just agreed to merge.
Read MorePlus, the U.S. just slapped new sanctions on Iran, the Labor Department’s December jobs report disappointed, and Six Flags received two downgrades from the same analyst in less than 24 hours.
Read MoreBuy Target -$13.10 or better Sell Target – TradersPro Sell Signal Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as […]
Read More